OBJECTIVE: Induction of heme oxygenase-1 (HO-1) has been demonstrated to result in chronic weight loss in several rodent models of obesity. However, the specific contribution of the HO metabolite, carbon monoxide (CO) to this response remains unknown. In this study, we determined the effect of chronic low level administration of a specific CO donor on the progression of obesity and its effects on metabolism and adipocyte biology in mice fed a high-fat diet. DESIGN: Experiments were performed on C57BL/6J mice fed a high-fat diet (60%) from 4 weeks until 30 weeks of age. Mice were administered either the CO donor, carbon monoxide releasing molecules (CORM)-A1 (5 mg kg À 1 , intraperitoneally every other day) or the inactive form of the drug (iCORM-A1). Body weights were measured weekly and fasted blood glucose, insulin as well as body composition were measured every 6 weeks. Food intake, O 2 consumption, CO 2 production, activity and body heat production were measured at 28 weeks after start of the experimental protocol. RESULTS: Chronic CORM-A1 attenuated the development of high fat induced obesity from 18 weeks until the end of the study. Chronic CORM-A1 treatment in mice fed a high-fat diet resulted in significant decreases in fasted blood glucose, insulin and body fat and increased O 2 consumption and heat production as compared with mice treated with iCORM-A1. Chronic CORM-A1 treatment also resulted in a significant decrease in adipocyte size and an increase in adipocyte number and in NRF-1, PGC-1a and UCP1 protein levels in epidydmal fat. CONCLUSION: Our results demonstrate that chronic CO treatment prevents the development of high-fat diet induced obesity via stimulation of metabolism and remodeling of adipocytes.
INTRODUCTION
The prevalence of obesity is increasing in populations worldwide. Obesity is often part of the metabolic syndrome, a condition which includes insulin resistance, dyslipidemian, reduced HDL cholesterol and hypertension. Metabolic syndrome increases the risk for development of cardiovascular diseases such as coronary artery disease, stroke and end-stage renal disease. 1, 2 Carbon monoxide (CO) is an odorless, colorless gas produced by combustion of carbon compounds such as those found in fossil fuels used in internal combustion engines. CO can be poisonous when levels in the air greater than 1500 parts per million (p.p.m.) are inhaled for a prolonged period of time, as CO alters oxygen transport in red blood cells resulting in severe tissue hypoxia. While we are exposed to CO in the environment, it is also produced endogenously in the body where it serves as a gaseous transmitter. [3] [4] [5] CO is produced via catabolism of heme by heme oxygenase (HO) enzymes and by oxidation of lipids. HO enzymes exist in two major isoforms: HO-1 and HO-2. HO-1 is a 32 kDa protein, which is inducible by a wide variety of stimuli including oxidants, metals and hypoxia. 6 HO-2 is a 36 kDa protein, which is the constitutively expressed isoform important in vascular function. 7, 8 Several studies have demonstrated that chemical induction or genetic overexpression of HO-1 can attenuate development of obesity. [9] [10] [11] [12] [13] Although increases in HO-1 expression attenuate obesity, the role of the HO metabolite, CO, in this response has not been specifically evaluated. Carbon monoxide releasing molecules (CORMs) are a class of compounds, which release CO in response to changes in pH or oxidant status. [14] [15] [16] [17] [18] CORM-A1 is a water soluble CO releasing molecule that does not contain a transition metal and thus releases CO over a longer half-life as compared with first generation CORMs. 19 As CORM-A1 lacks transition metals, which are present in CORMs such as CORM-2 and 3, the inactive form of this compound does not induce HO-1 so that the specific effect of increases in CO alone can be evaluated. 20 In the present study, mice were treated every other day over a 30-weektime frame with a low-dose of CORM-A1 in order to determine the specific effect of chronic, low-dose CO treatment on development of obesity in response to a high-fat diet.
MATERIALS AND METHODS Animals
Oxygen consumption, carbon dioxide production and motor activity At 28 weeks after the start of the experimental protocol CORM-A1 treated, iCORM-A1 treated or control mice were placed individually in an acrylic cage (16 cm Â 24 cm Â 17 cm) equipped with a metabolic monitoring system (AccuScan system, Harvard Apparatus, Holliston, MA, USA) for measurements of oxygen consumption (VO 2 ), carbon dioxide production (VCO 2 ) and respiratory quotient (RQ) as previously described.
12 VO 2 , VCO 2 and RQ were determined daily (for 2 min every 10-min interval) and expressed as the 24 h average. RQ was calculated by the formula: VCO 2 / VO 2 . Motor activity was determined using infrared light beams mounted in the cages in x, y, and z axes. Heat production was derived from the following formula (4.33 þ (0.67*RQ)*VO 2 *weight (g)*60). After the mice were acclimatized to the new environment for 1 day, VO 2, VCO 2 , RQ and animal activity were recorded for 2 consecutive days.
Glucose tolerance test
For glucose tolerance tests, mice were subjected to fasting overnight (B16 h) and D-glucose (1 g per kg of body weight) was injected intraperitoneally. Blood glucose was monitored at 0, 15, 30, 60 and 90 min after glucose injection.
Food consumption
Food consumption was measured during week 29 of mice receiving CORM-A1 or iCORM-A1 injections. The total amount of Food was weighed daily in the morning for 5 consecutive days. The daily consumption over the 5-dayperiod was averaged for each mouse to obtain 24-h food consumption.
Adipocyte staining and counting
To determine the effects of treatment on adipocyte morphology, visceral and subcutaneous fat was excised immediately after euthanasia. For analysis of adipocyte size, fat pads of mice from each group were fixed in formalin and embedded in paraffin, cut in 5 mm section and stained with hematoxylin and eosin. Adipocyte size was determined at Â 100 magnification using a color video camera attached to a Nikon microscope by Metamorph software (Universal Imaging Corporation, Downingtown, PA, USA). To ensure accuracy of measurement, three images of each animal were analysed by three different investigators and averaged into a single measurement. Measurements were obtained from three individual animals per group. Data is presented as the average ±s.e. for each group.
Western blot analysis
Western blots were performed on lysates prepared from tissues collected at the end of the experiments. Samples of 30 mg of protein were boiled in Laemmli sample buffer (Bio-Rad, Hercules, CA, USA) for 5 min and electrophoresed on 10 or 12.5% SDS-polyacrylamide gels and blotted onto nitrocellulose membrane. Membranes were blocked with Odyssey blocking buffer (LI-COR, Lincoln, NE, USA) for 2 h at room temperature and then incubated with primary antibodies overnight at 4 1C. Membranes were incubated with either Alex 680 (Molecular Probes, Grand Island, NY, USA) or IRDye 800 (Rockland, Gilbertsville, PA, USA) secondary antibodies for 1 h at room temperature. Membranes were visualized using an Odyssey infrared imager (Li-COR), which allows for the simultaneous detection of two proteins. Densitometry analysis was performed using Odyssey software (LI-COR Adiponectin, leptin and insulin Plasma adiponectin, insulin and leptin concentrations were determined by ELISAs (Millipore adiponectin ELISA kit (Millipore, Billerica, MA, USA) Linco Insulin ELISA kit (Millipore) and R&D leptin ELISA kit (Minneapolis, MN, USA)) as previously described. 12 
Statistics
All data are presented as mean ± s.e.m. Differences between treatment groups were determined using one-way analysis of variance with a post hoc test (Dunnett's). A Po0.05 was considered to be significant. All analyses were performed with SigmaStat (Systat software Inc., Richmond, CA, USA).
RESULTS
Chronic CORM-A1 treatment attenuates weight gain and decreases fat mass in mice fed a high-fat diet High fat feeding in mice resulted in significant elevations in body weight as compared with mice fed standard chow by week 10 of the study. CORM-A1 treatment resulted in reduced body weight starting at week 19 and remained lower in the CORM-A1-treated mice as compared with the iCORM-A1, which is the inactive form of the CO donor, treated mice throughout the duration of the study (Figure 1 ). Fat mass as measured by echo-MRI was increased in both groups of high-fat fed mice as compared with control mice fed a standard chow. However, fat mass was significantly decreased in CORM-A1 as compared with iCORM-A1-treated mice at 12, 18 and 24 weeks (Figure 2a ). No differences in lean mass were detected between the groups at 12, 18, 24 or 30 weeks of age ( Figure 2b ). Fat pad weight measured at the end of the study was impacted by chronic treatment of CORM-A1. Epididymal fat was significantly increased in iCORM-A1-treated mice as compared with both CORM-A1 and control mice ( Figure 2c ). Visceral fat was increased in both groups of mice fed a high-fat diet as compared with control mice but visceral fat weight was significantly higher in iCORM-A1-treated versus CORM-A1-treated mice ( Figure 2c ). Total fat was also increased in both groups of mice fed a high-fat diet as compared with control mice but the Chronic CORM-A1 treatment lowers blood glucose and insulin, increases glucose clearance and decreases plasma leptin in mice fed a high-fat diet Fasted blood glucose levels in both groups of mice fed a high-fat diet were increased at both 24 and 30 weeks of treatment as compared with control mice (Figure 3a ). However, fasted blood glucose levels were significantly lower in CORM-A1-treated as compared with iCORM-A1-treated mice at both time frames (Figure 3a ). Plasma insulin levels were increased at both 24 and 30 weeks in both groups of mice fed a high-fat diet as compared with control mice (Figure 3b ). CORM-A1 treatment resulted in 30% decrease in plasma insulin levels as compared with iCORM-A1-treated mice at both 24 and 30 weeks (Figure 3b ). In order to access in vivo insulin function, we performed a glucose tolerance test at 30 weeks of age. iCORM-A1-treated mice exhibited a significantly increased delay in the clearance of glucose as indicated by the greater area under the curve, as compared with CORM-A1 and control mice (Figure 3c) . No difference in glucose clearance was detected between control and high-fat fed CORM-A1-treated mice. Plasma adiponectin levels measured at week 30 were decreased in both groups of mice fed a high-fat diet as compared with control mice (Figure 3d ). Plasma leptin levels were increased in both groups of mice fed a high-fat diet as compared with control mice ( Figure 3e) ; however, plasma leptin levels were reduced by 70% in CORM-A1-treated mice as compared with iCORM-A1-treated mice (Figure 3e ).
Chronic CORM-A1 treatment increases oxygen consumption and heat production but has no effect on food consumption or physical activity in mice fed a high-fat diet In order to determine the effect of chronic CORM-A1on metabolism, mice were placed in metabolic chambers at 28 weeks of treatment for measurement of oxygen consumption, carbon dioxide production, heat production and activity. Oxygen consumption when normalized to the lean body weight as measured by echo-MRI was significantly elevated in the CORM-A1-treated mice on the high-fat diet as compared with both iCORM-A1-treated and control mice fed a standard diet (Figure 4a ). Carbon dioxide production when normalized to lean body weight was increased in the CORM-A1-treated mice as compared with both iCORM-A1 and control mice but this increase did not achieve statistical significance (Figure 4b ). Heat production was significantly increased in CORM-A1-treated mice as compared with both iCORM-A1 and control mice (Figure 4c ). High fat feeding resulted in a significant decrease in activity as compared with control mice, which was not reversed by CORM-A1 treatment (Figure 4d ). Measured over a 5-day-period at 29 weeks after commencement of injections, food intake was not different between any of the groups; however, the caloric intake of the mice fed a high-fat diet was higher than that of the mice fed a normal-fat diet (Figure 4e ).
Chronic CORM-A1 treatment remodels adipocyte size and number The effect of chronic CORM-A1 treatment on adipocyte number and morphology was determined in sections of epididymal fat obtained at the end of the experimental protocol. High-fat diet resulted in a decrease in number and an increase in epididymal adipocyte size as compared with mice fed a standard diet ( Figure 5 ). CORM-A1 treatment resulted in a significant increase in epididymal adipocyte number as compared with iCORM-A1-treated mice (Figure 5d ). CORM-A1 also resulted in a significant decrease in epididymal adipocyte size as compared with iCORM-A1-treated mice (Figure 5e ). No significant differences in adipocyte number or size were detected in the subcutaneous fat between any of the groups (Supplementary Figure 1) .
Chronic CORM-A1 treatment induces markers of mitochondrial biogenesis and browning of fat in adipocytes from mice fed a high-fat diet In samples of epidydimal fat, chronic CORM-A1 treatment increased levels of peroxisomal proliferating activating receptorg coactivator (PGC-1a) and nuclear respiratory factor-1 (NRF-1), which are considered markers of mitochondrial biogenesis ( Figures 6a, d and e) . Levels of uncoupling protein-1 (UCP1) were also increased in epidydimal fat of CORM-A1-treated mice (Figures  6a and f) . The levels of HO-1 were increased in the epidydimal fat of both groups of mice fed a high-fat diet as compared with control mice on a normal fat diet (Figures 6a and c) .
In subcutaneous fat, chronic CORM-A1 treatment increased levels of and PGC-1a and NRF-1 similar to what was observed in epidydimal fat (Supplementary Figures 2A, D and E) . The levels of UCP1 were increased in the subcutaneous fat in CORM-A1-treated mice ( Supplementary Figures 2A and F) . In contrast to epididymal fat, the levels of HO-1 were reduced in both groups of mice fed a high-fat diet as compared with lean, control mice ( Supplementary  Figures 2A and C) . The levels of aldehyde dehydrogenase-1(ALDH1A1), were increased in iCORM-A1-treated mice fed a high-fat diet but were normalized in mice chronically treated with CORM-A1 ( Supplementary Figures 2A and B) . HO-1 levels in the brown fat were increased in both groups of mice fed a high-fat diet as compared with lean, control mice ( Figure 7) . CORM-A1 treatment resulted in a significant increase in UCP1 levels in the brown fat as compared with lean, control mice but not high-fat mice treated with iCORM-A1 (Figure 7 ).
Chronic CORM-A1 treatment induces hypoxia inducible factor 1-a (HIF-1a) but not vascular endothelial derived growth factor (VEGF) or collagen levels in epidydmal fat The levels of HIF-1a, as well as the levels of VEGF were measured in samples of epidydmal fat from mice in each treatment groups. HIF-1a levels were significantly elevated in the epidydmal fat of CORM-A1 mice as compared with both iCORM-A1 and control mice (Figures 8a and b) . VEGF levels were also significantly increased in CORM-A1-treated mice as compared with both iCORM-A1-treated mice on a high-fat diet and control mice on a normal-fat diet (Figures 8a and c) . In order to further address adipocyte remodeling, the levels of collagen I and III, as well as fibronectin levels were measured in samples of epidydmal fat from mice in each treatment group. No differences in collagen I or III levels were detected between the groups (Figures 8a, d and e). Fibronectin levels were decreased by high-fat diet treatment and CORM-A1 treatment had no effect on this response (Figures 8a and f) .
DISCUSSION
Our results demonstrate the chronic low-dose treatment with a CO donor, CORM-A1, attenuates the development of obesity and remodels existing adipocytes in mice fed a high-fat diet. The dose of CORM-A1 utilized in the present study was based on previous studies, which have demonstrated that this dose of CORM-A1 (5 mg kg À 1 ) does not significantly elevate blood carboxyhemoglobin levels when measured up to 120 min after administration. 22 Thus, chronic low-dose CORM-A1 treatment as utilized in the present study would have no adverse side-effects due to increases in blood carboxyhemoglobin and interference with oxygen delivery to the tissues. It is not known if a higher dose of CORM-A1, one that would result in a mild 20-25% increase in blood carboxyhemoglobin levels, would have a greater effect to promote further weight loss and remodeling of adipocytes.
Chronic treatment with the CO donor resulted in significant increases in oxygen consumption and heat production without any effects on food intake in mice fed a high-fat diet. The effect of CO donor treatment on oxygen consumption and heat production were similar to effects of chronic HO-1 induction in obese melanocortin-4 receptor-deficient mice. 12 The effects of CO donor treatment to increase oxygen consumption without altering food intake suggest that chronic CO donor treatment causes weight loss through increases in metabolism. The increase in metabolism in response to chronic CO donors may be mediated by alterations in mitochondrial function. There are several observations in the literature and in the present study that support the role of increased mitochondrial function in mediating the increase in metabolism in chronic CO-treated mice fed a high-fat diet. Previous studies have demonstrated that CO increases mitochondrial biogenesis in the heart and skeletal muscle. [23] [24] [25] The increase in mitochondrial biogenesis in these tissues was mediated via increases in NRF1 and PGC-1a. 25, 26 In the present study, chronic CO treatment increased the levels of these proteins in the fat and resulted in changes in adipocyte number and morphology in the epidydimal fat depot.
CO treatment can also have significant effects on mitochondrial function in addition to effects on biogenesis. CO increases intracellular ATP levels in both cultured astrocytes and hepatocytes through soluble guanylyl cyclase dependent and independent mechanisms. 27, 28 One way in which CO may improve mitochondrial efficiency is through its effect on mitochondrial respiration. CO has been reported to have different effects on mitochondrial respiration depending on the levels to which mitochondria are exposed. 29 At low levels (1 mM and below) CO increases respiratory control ratio and increases mitochondrial transmembrane potential, while at higher levels (45 mM) CO has the opposite effect. A recent study in high-fat fed mice demonstrated that acute treatment (two injections separated by 16 h after 12 weeks on the diet) with the CO donor, CORM-3, improved state 3 respiration, increased mitochondrial membrane potential and improved cardiac function. 30 Although it is difficult to determine the actual concentration of CO that the adipocytes were exposed to in the present study, it is more likely that it would be closer to the lower end (o1 mM) as the dose of CORM-A1 administered in the present study failed to increase blood carboxyhemoglobin levels. CO treatment can also increase oxygen consumption and heat production through mitochondrial uncoupling. 29, 31, 32 Although the exact mechanism by which CO causes mitochondrial uncoupling is not known, results from the present study clearly demonstrate that chronic CO treatment results in increases in UCP1 in both epidydimal and subcutaneous adipocytes but not in brown fat. The important roles of both UCPs and adenine nucleotide transporter (ANT) in CO-mediated mitochondrial uncoupling were recently demonstrated in isolated cardiac mitochondria. 32 The increase in UPC-1 levels in adipocytes could be responsible for the increase in heat production that was exhibited by mice chronically treated with CORM-A1 in the present study.
An emerging strategy to curb development of obesity is the conversion of white fat to more metabolically active beige fat phenotype or the 'browning' of white adipose tissue. It is believed that by converting energy storing white fat to energy burning brown fat that this can result in an increase in energy expenditure. 33, 34 One of the key regulators in the transition of white fat to brown fat is aldehyde dehydrogenases. Mice deficient in Aldh1A1 are resistant to the development of high-fat diet induced obesity and also display an increase in metabolic rate and body temperature. 35 The retinoid receptor signaling pathway also has an X receptor. 36, 37 Alhds are the rate limiting step in the conversion of retinaldehyde to retinoic acid. Recent studies have demonstrated that increased levels of aldehyde dehydrogenases are associated with obesity and that blockade of Aldh1a1 stimulates thermogenic reprogramming of white fat. 38 In the present study, chronic CO treatment resulted in a significant decrease in Aldh1a1 protein levels in subcutaneous fat suggesting a novel link between retinol metabolism and CO in adipocytes. The mechanism by which CO decreases Alhd1a1 protein in fat is not known and merits further investigation.
Although we have previously demonstrated that the dose of CORM-A1 utilized in the present study does not result in any increase in blood carboxyhemoglobin levels, 22 it is still possible that the CO released could cause local adipose hypoxia, which may contribute to the observed effects on body weight in the present study. Consistent with this hypothesis, the levels of the hypoxia marker HIF-1a were significantly increased in epidydmal fat from the CORM-A1-treated mice. Likewise, a similar increase was observed in the HIF-1a target gene, VEGF. These results suggest that the CO released could cause local hypoxia of the adipose tissue. Recent studies have demonstrated that exposure to high altitude hypoxia can also result in weight loss. [39] [40] [41] However, the primary mechanism for weight loss in response to high altitude hypoxia appears to be mediated through decreases in food intake rather than increases in metabolic rate. We did not observe any differences in food intake in our mice chronically treated with CORM-A1 so it is likely that the mechanism of weight loss observed in the present study is independent from any effects of generalized hypoxia.
Induction of HO-1 in obesity has been linked to increases in adiponectin, [9] [10] [11] [12] although the mechanism by which this occurs is not known. Chronic CO treatment failed to increase plasma adiponectin levels, which were decreased in response to the chronic high-fat diet. This would suggest that the ability of HO-1 to increase plasma adiponectin levels occurs independently of CO production and could be mediated through increases in bilirubin levels or simply by the HO-1 protein itself through some yet unknown mechanism. Although chronic CO treatment had no effect on plasma adiponectin, it resulted in a significant decrease in the levels of leptin in the plasma. This result is likely due to the significant decrease in adiposity as a result of chronic CO treatment. Previous studies in obese melanocortin-4 receptordeficient mice demonstrated that weight loss with HO-1 induction resulted in a significant increase in physical activity. 12 In the present study, although CO treatment resulted in a significant decrease in body weight, it was unable to increase physical activity in mice fed a high-fat diet. These results suggest that a high-fat diet effects physical activity via a mechanism that is independent of body weight and one that is not affected by chronic CO treatment but is by induction of HO-1. Our results establish low level chronic CO treatment as a potential anti-obesity treatment. Chronic CO treatment can enhance metabolism through upregulation of mitochondrial biogenesis, mitochondrial uncoupling and the remodeling of white adipose tissue. Further studies are required to identify the specific mechanisms by which chronic CO treatment mediates these effects in obesity.
